Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ixazomib
Drug ID BADD_D01223
Description Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Indications and Usage Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Marketing Status Prescription
ATC Code L01XG03
DrugBank ID DB09570
KEGG ID D10130
MeSH ID C548400
PubChem ID 25183872
TTD Drug ID Not Available
NDC Product Code 63020-230; 63020-080; 63020-079; 63020-078; 63020-390; 63020-400
Synonyms ixazomib | MLN 9708 | MLN9708 | MLN-9708 | Ninlaro
Chemical Information
Molecular Formula C14H19BCl2N2O4
CAS Registry Number 1072833-77-2
SMILES B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.019--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.0010.001598%
Cholelithiasis09.03.01.0020.000533%Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Colitis07.08.01.001--
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.0010.009058%
Cough22.02.03.0010.003996%
Cystitis20.03.02.002; 11.01.14.0010.000799%
Death08.04.01.0010.038433%
Dehydration14.05.05.001--
Dementia19.20.02.001; 17.03.01.0010.000533%Not Available
Depressed mood19.15.02.001--Not Available
Diarrhoea07.02.01.0010.036232%
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry eye06.08.02.0010.001332%
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.0010.002398%
Dyspepsia07.01.02.0010.001865%
Dysphonia17.02.08.004; 22.02.05.005; 19.19.03.002--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.0030.000533%Not Available
Encephalopathy17.13.02.001--
Epistaxis22.04.03.001; 24.07.01.005--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000799%
Eye discharge06.04.05.0010.000533%Not Available
Eye disorder06.08.03.0010.000799%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages